

Peer Review File

Article information: <https://dx.doi.org/10.21037/jlpm-23-12>

Reviewer Comments

Reviewer A

Comment 1: High-density lipoprotein binding protein 1: new markers for cardiovascular diseases among noncommunicable diseases: a brief narrative review
Comprehensive review highlighting potential role of LPL Mass in predicting TRL and CV risk.

A central illustration highlighting potential importance of LPL mass in terms of lipoprotein biology and risk evaluation would make paper easier to read.

Reply 1: We appreciate the comment. We added a central illustration highlighting potential importance of LPL as Figure 1. We also added the legend for Figure 1.

Reviewer B

Comment 1: What are the kinetics of LPL and TRL in blood in maintenance hemodialysis patients who receive heparin on a regular basis?

Reply 1: We appreciate the comment. We added several sentences which describe LPL and TRLs in hemodialysis patients treated with heparin. Please find line 354-361. Citations 164 and 165 have been added along with this postscript.

Comment 2: An overview of primary hyperchylomicronemia resulting from LPL dysfunction or LPL deficiency could be added.

Reply 2: We appreciate the comment. We added the following sentences on lines 117-119. Please confirm. "Genetic alterations affecting LPL activity are summarized by Shaik et al. LPL activity is elevated by loss of function of apoC3, ANGPTL3 and ANGPTL4 and decreased by loss of function of apoA5. (2, 3) (Figure 1)."

Comment 3: Why not also cite a paper showing that therapeutic interventions such as increasing pre-heparin LPL mass may contribute to the demand for CV events? (J Atheroscler Thromb. 2022 Apr 1;29(4):451-463.)

Reply 3: We appreciate the comment. We cited the article as reference 151, and modified table 2. Please confirm.

Comment 4: Certain statins have been reported to increase serum LPL mass (J Atheroscler Thromb.2004;11(6):341-7.) and LPL expression in tissues (J Atheroscler Thromb, 2006;13(2):122., Metabolism, 2012 Oct;61(10):1452-60.). Table 2 may therefore require modification.

Reply 4: We cited these reports, and modified the table 2. Reference 156 and 157 are not in vivo investigation. Therefore, we did not add these reports in table 2. We also added several sentences on line 342-344. Please confirm. (An article was already cited). J Atheroscler Thromb.2004;11(6):341-7. We already cited this article as reference 146.

J Atheroscler Thromb, 2006;13(2):122., We cited this article as reference 156.
Metabolism, 2012 Oct;61(10):1452-60. We cited this article as reference 157.

Comment 5: Other agents such as Insulin, angiotensin II receptor antagonist and 5-hydroxytryptamine_{2A} receptor antagonist are also known to increase serum LPL mass. This information should be cited as a priority over konnyaku.

Reply 5: We appreciate the comment. We cited these reports as reference 158 and 159. We added several sentences on line 345-347 and modified the table 2. Please confirm.